Skip to main content

Table 2 Associations between polymorphisms in GST genes and skin toxicity (≥2c) following radiation therapy for breast cancer

From: Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study

Genotypes

Patients

Toxicities

HRa (95% CI)

GSTM1

   

   Present

215

36

1.0

   Absent

213

39

1.23 (0.74–2.03)

GSTT1

   

   Present

384

69

1.0

   Absent

55

6

0.73 (0.29–1.86)

GSTA1

   

   GG

149

29

1.0

   GA

194

35

1.09 (0.65–1.82)

   AA

87

12

0.85 (0.43–1.71)

   

P (trend) = 0.44

GSTP1

   

   AA

176

27

1.0

   AG

213

39

1.38 (0.83–2.30)

   GG

38

10

2.28 (1.04–4.99)

   

P (trend) = 0.04

  1. aHazard ratio adjusted for clinic, photon field, beam energy, boost method, BMI, smoking status, alcohol consumption, and hormone therapy; numbers vary because of missing data. CI, confidence interval; GST, glutathione S-transferase; HR, hazard ratio.